Clinical observation of piperacillin/tazobactam's optimized regimen formulated by T >MIC% for 59 patients with P.aeruginosa infection

LI Yi; SONG Xiangqing; GUI Wandi

doi:10.3969/j.issn.1006-0111.2017.03.017

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To observe the treatment efficacy of piperacillin/tazobactam regime for P.aeruginosa infection formulated by the method of the ratio of T above MIC (T >MIC%). Methods 59 hospitalized patients with P.aeruginosa infection were diagnosed by etiological diagnosis which was sensitive to piperacillin/tazobactam from Jan. to April.2015. Before treatment, all patients were randomly divided into the control group and the test group. Patients in the control group were treated with 4.5 g piperacillin/tazobactam once and repeated every six hours. Patients in test group were treated with 4.5 g piperacillin/tazobactam once and repeated every twelve hours. The two groups were injected by 15 mg/kg amikacin once a day based on the above program. The other treatments were kept to be same. Results Between the two groups, the clinical efficiency rate and total hospital stay were equivalent, bacterial clearance rate and incidence of adverse reactions were similar, there were no difference between CRP and APACHE Ⅱ score before and after treatment. Conclusion The regime of piperacillin/tazobactam for P.aeruginosa infection formulated by the method of the ratio of T above MIC (T >MIC%)was safe, effective and feasible.

Clinical observation of piperacillin/tazobactam's optimized regimen formulated by T >MIC% for 59 patients with P.aeruginosa infection

1. Department of Pharmacy, Jiangxia First People's Hospital, Wuhan 430200, China

2. Department of Pharmacy, Hunan Cancer Hospital, Changsha, 410013, China

3. Department of Internal Medicine, Jiangxia First People's Hospital, Wuhan 430200, China

Received Date: 2015-12-22

Rev Recd Date: 2016-06-02

Key words:

piperacillin/tazobactam /
P.aeruginosa /
pharmacokinetics/pharmacodynemics theory /
times above MIC

Abstract: Objective To observe the treatment efficacy of piperacillin/tazobactam regime for P.aeruginosa infection formulated by the method of the ratio of T above MIC (T >MIC%). Methods 59 hospitalized patients with P.aeruginosa infection were diagnosed by etiological diagnosis which was sensitive to piperacillin/tazobactam from Jan. to April.2015. Before treatment, all patients were randomly divided into the control group and the test group. Patients in the control group were treated with 4.5 g piperacillin/tazobactam once and repeated every six hours. Patients in test group were treated with 4.5 g piperacillin/tazobactam once and repeated every twelve hours. The two groups were injected by 15 mg/kg amikacin once a day based on the above program. The other treatments were kept to be same. Results Between the two groups, the clinical efficiency rate and total hospital stay were equivalent, bacterial clearance rate and incidence of adverse reactions were similar, there were no difference between CRP and APACHE Ⅱ score before and after treatment. Conclusion The regime of piperacillin/tazobactam for P.aeruginosa infection formulated by the method of the ratio of T above MIC (T >MIC%)was safe, effective and feasible.

HTML

Reference (14)

[1]	Dagan R,Klugman KP,Craig WA,et al.Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy[J].J Antimicrob Chemother,2001,47(2):129-140.
[2]	Cazzola M,Di Perma F,Boveri B,et al.Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacetbation of chronic bronchitis[J].J Chemother,2000,12(3):216-222.
[3]	Shea KM,Cheatham SC,Smith DW,et al. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients[J].Ann Pharmacother,2009,43(11):1747-1754.
[4]	Peric M,Browne FA,Jacobs MR,et a1.Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquimd infections:use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents[J].Clin Ther,2003,25(1):169-177.
[5]	中华医学会呼吸病学分会感染学组.铜绿假单胞菌下呼吸道感染诊治专家共识[J].中华结核和呼吸杂志,2014,37(1):9.
[6]	姚欣凯,李苌清,吴亚陵,等.应用PK/PD模型和蒙特卡洛模拟优化ICU中铜绿假单胞菌感染的初始给药方案[J].中国药房,2015,26(8):1060-1062.
[7]	李耘,吕媛,薛峰,等.卫生部全国细菌耐药监测网(Mohnarin)2011-2012年革兰阴性菌耐药监测报告[J].中国临床药理学杂志,2014,30(3):260-277.
[8]	施晓群,孙景勇,倪语星,等.2011年中国CHINET铜绿假单胞菌耐药性监测[J].中国感染与化疗杂志,2013,13(3):218-221.
[9]	李小芳,宋香清.哌拉西林他唑巴坦抗铜绿假单胞菌感染的T >MIC%的推导及在方案评价与优化中的作用[J].中国药师,2015,18(7):1086-1091.
[10]	冒国光,章辉,张道友,等.注射用哌拉西林/舒巴坦治疗呼吸和泌尿系统感染多中心临床研究[J].药学与临床研究,2011,19(1):13-17.
[11]	何聪,申丽旻,杜全胜,等.根据PK/PD理论指导哌拉西林他唑巴坦治疗革兰阴性杆菌感染的临床观察[J].临床合理用药杂志,2014,7(10A):41-42.
[12]	王丽,马杰,李顺清,等.重症监护病房革兰阴性杆菌耐药性监测[J].中华医院感染学杂志,2007,17(9):1145-1146.
[13]	庞晓军,杜正隆,梁耿,等.临床药师参与危重病患者的药学服务[J].中国医院药学杂志,2010,30(17):1495-1497.
[14]	张玲,艾青.感染与C-反应蛋白的关系[J].吉林医学,2000,21(6):333-334.

Message Board

Clinical observation of piperacillin/tazobactam's optimized regimen formulated by T >MIC% for 59 patients with P.aeruginosa infection

doi: 10.3969/j.issn.1006-0111.2017.03.017

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views